NEW YORK – Molecular oncology startup SEngine Precision Medicine announced today that it has raised $5.1 million in a Series A financing round.
The Seattle-based firm will use the funding to improve AI integration and further develop its PARIS 3D tumor organoid diagnostic and drug discovery platform. The tool combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with targeted drug therapies.
The financing round was led by Bangarang Group, with participation from various family offices and other returning investors. According to SEngine, the round brings its total funding thus far to $9 million.
"This round of financing positions us to move quickly to both commercialize and scale our technology," SEngine Founder and CEO Carla Grandori said in a statement. "We're proud of the market validation and our clinical validation to continue to advance efforts we believe will revolutionize personalized and effective cancer care."
In September, SEngine partnered with San Francisco-based Atomwise to develop personalized treatments for cancer.